SMITHKLINE BEECHAM PAXIL U.S. SALES REACH $135 MIL. IN FIRST 10 MONTHS ON MARKET; COMPANY's 1993 U.S. PHARMACEUTICAL SALES INCREASE 11% TO $2.42 BIL.
Executive Summary
SmithKline Beecham's Paxil antidepressant posted U.S. sales of $135 mil. in its first 10 months on the market, the company reported Feb. 22.